Cardiovascular drugmaker Kiniksa's Q1 net income rises

Kiniksa Pharmaceuticals International

28/04/2026 12:38

Overview

Biopharmaceutical firm's Q1 ARCALYST revenue grew 56% yr/yr to $214.3 mln

Q1 net income rose to $22.6 mln from $8.5 mln a year earlier

Company raised 2026 ARCALYST revenue guidance to $930-$945 mln

Outlook

Kiniksa raises 2026 ARCALYST net product revenue guidance to $930-$945 mln from $900-$920 mln

Result Drivers

ARCALYST ADOPTION - Co said revenue growth was driven by expanding adoption of ARCALYST for recurrent pericarditis

PRESCRIBER GROWTH - Growth in both new and repeat ARCALYST prescribers provided momentum for the franchise

Company press release: ID:nGNX2LtJWc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Revenue
$214.27 mln
Q1 EPS
$0.27
Q1 Net Income
$22.59 mln
Q1 Operating Expenses
$185 mln
Q1 Pretax Profit
$32.68 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $58.00, about 33% above its April 27 closing price of $43.61

The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 24 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)